We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Expanded Genetic Testing Leads to Additional Cardiomyopathy, Arrhythmia Diagnoses

By LabMedica International staff writers
Posted on 17 Aug 2022
Print article
Image: Gross pathology of idiopathic cardiomyopathy. Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium. (Photo courtesy of Dr. Edwin P. Ewing, Jr)
Image: Gross pathology of idiopathic cardiomyopathy. Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium. (Photo courtesy of Dr. Edwin P. Ewing, Jr)

Genetic testing for nonischemic cardiomyopathies and inherited arrhythmias is recommended by cardiovascular societies to establish a genetic diagnosis, guide clinical management, and identify family members at risk.

However, many individuals with cardiomyopathies or arrhythmias do not receive genetic testing and therefore cannot benefit from gene-specific clinical management. Barriers to testing include limited clinician knowledge of genetics and results interpretation as well as real and perceived concerns regarding cost, insurance coverage, and low diagnostic yields.

Medical Scientists at the Feinberg School of Medicine (Chicago, IL, USA) and their colleagues performed a cohort study that involved a retrospective review of DNA sequencing results for cardiomyopathy- and arrhythmia-associated genes. The study included 4,782 patients with a suspected genetic cardiomyopathy or arrhythmia who were referred for genetic testing by 1,203 clinicians; all patients participated in a no-charge, sponsored genetic testing program for cases of suspected genetic cardiomyopathy and arrhythmia at a single testing site from July 12, 2019, through July 9, 2020.

Next-generation sequencing gene panels were used to simultaneously test for both sequence and exon-level copy number variants. Up to 150 genes associated with cardiomyopathies or arrhythmias were sequenced. The primary panel included 67 genes with established associations with cardiomyopathies and arrhythmias. Four optional add-on panels that included genes with preliminary associations with cardiomyopathies and arrhythmias could be ordered initially or after receipt of initial results without charge. Each gene was targeted with oligonucleotide baits (Agilent Technologies, Santa Clara, CA, USA; Roche, Pleasanton, CA, USA; Integrated DNA Technologies, Coralville, IA, USA) that were designed to capture exons and 10 bases of flanking intronic sequences.

The investigators reported that among 4,782 patients (mean age, 40.5± 21.3 years; 2,551 male [53.3%]) who received genetic testing, a positive result (molecular diagnosis) was confirmed in 954 of 4,782 patients (19.9%). Of those, 630 patients with positive results (66.0%) had the potential to inform clinical management associated with adverse clinical outcomes, increased arrhythmia risk, or targeted therapies. Combined cardiomyopathy and arrhythmia gene panel testing identified clinically relevant variants for 15 patients suspected of having a genetic cardiomyopathy or arrhythmia. If only patients with a high suspicion of genetic cardiomyopathy or arrhythmia had been tested, at least 137 positive results (14.4%) would have been missed.

If testing had been restricted to panels associated with the clinician-provided diagnostic indications, 75/689 positive results (10.9%) would have been missed; 27/75 findings (36.0%) gained through combined testing involved a cardiomyopathy indication with an arrhythmia genetic finding or vice versa. Cascade testing of family members yielded 402 of 958 positive results (42.0%). Patients referred for arrhythmogenic cardiomyopathy had the lowest rate of variants of uncertain significance (81/176 patients [46.0%]), and patients referred for catecholaminergic polymorphic ventricular tachycardia had the highest rate (48/76 patients [63.2%]).

Elizabeth M. McNally, MD, PhD, Professor of Genetic Medicine and senior author of the study said, “Notably, this study found a 10.9% gain in genetic diagnoses that would have been missed if testing had been limited to genes associated with a single cardiomyopathy or arrhythmia subtype.”

The authors concluded that comprehensive genetic testing for cardiomyopathies and arrhythmias revealed diagnoses that would have been missed by disease-specific testing. In addition, comprehensive testing provided diagnostic and prognostic information that could have potentially changed management and monitoring strategies for patients and their family members. They added that the benefits of identifying additional cases outweighs the risks posed by detecting variants of uncertain significance, which were found in 51.2% of their cohort. The study was published on August 10, 2022 in the journal JAMA Cardiology.

Related Links:
Feinberg School of Medicine 
Agilent Technologies 
Roche
Integrated DNA Technologies 

Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
New
Hemoglobin A1c Control
HbA1c (Auto)
New
STI Test
Rheonix STI TriPlex Assay
New
TSI Stimulating Assay
Thyretain TSI Stimulating Reporter BioAssay

Print article
IIR Middle East

Channels

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.